两种方案治疗晚期胃癌的临床对照研究  

Clinic control study of two regimens for advanced gastric cancer

作　　者：赖邻宁[1] 马小南[1] 杜敏[1] 祝艳华[1] 杜华昆[1] 

机构地区：[1]大连市中心医院肿瘤科,辽宁大连116033

出　　处：《中国医药导报》2012年第2期28-31,共4页China Medical Herald

摘　　要：目的比较伊立替康联合替吉奥（S-1）与单纯S-1两种不同方案治疗晚期胃癌的疗效及不良反应。方法回顾性分析2009年3月~2011年7月于我院治疗的晚期胃癌患者65例,采用伊立替康联合S-1治疗的30例为试验组,采用S-1治疗的35例患者为对照组。结果试验组和对照组有效率分别为43.33%和14.29%,差异有统计学意义（P=0.006）。中位疾病进展时间分别为4.5个月和3.0个月,差异有统计学意义（P=0.041）。中位总生存期分别为7.5个月和6.5个月,差异无统计学意义（P〉0.05）。不良反应：试验组出现普遍,均可控制,对照组不良反应轻微,试验组和对照组Ⅲ/Ⅳ腹泻分别为13.33%和2.86%,差异有统计学意义（P=0）。Ⅲ/Ⅳ度中性粒细胞减少分别为13.33%和2.86%,差异有统计学意义（P=0）。结论伊立替康联合S-1疗效肯定、应用方便、耐受性较好,一、二线化疗均适合。对不能耐受两药联合化疗的病例,单药S-1仅推荐一线治疗。Objective To compare the curative effect and the toxicity of the regimen of S-1 combined with irinotecan,and S-1 for advanced gastric cancer.Methods Patients with advanced gastric cancer to treat in our hospital form March 2009 to July 2011 were analyzed retrospectively,and divided into experiment group and control group,patients in experiment group were received the regimen of S-1 combined with irinotecan.Patients in control group were treated with S-1.Results Effective rate were 43.33% and 14.29% in experiment group and control group respectively,there were statistic difference between two groups（P = 0.006）.The median TTP in experiment group and control group were 4.5 months and 3.0 months respectively,there was a statistic difference between two groups（P = 0.041）.The median OS in experiment group and control group were 7.5 months and 6.5 months respectively,the difference in two groups was not statistically significant（P 0.05）.Adverse effects of experiment group were generally,all could be controlled,Adverse effects of control group were gently.3/4 diarrhea were 13.33% and 2.86% in experiment group and control group respectively,there was a statistic difference between two groups（P = 0）.3/4 neutropenia were 13.33% and 2.86% in experiment group and control group respectively,there was a statistic difference between two groups（P = 0）.Conclusion S-1 combined with irinotecan is convenient,safe and promising for the patients with advanced gastric cancer.The regime is worthy to be recommended as first-line or second-line chemotherapy,for the patients who can not tolerant combination chemotherapy,recommend S-1 alone to first-line.

关 键 词：胃肿瘤 替吉奥 伊立替康 化学治疗 对照研究 

分 类 号：R735.2[医药卫生—肿瘤]